University of Zurich
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Private
- Established
- 1833-04-29
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.uzh.ch
Arcturus Therapeutics to Present Phase 2 Data for ARCT-810 mRNA Therapy in Rare Genetic Disorder
Arcturus Therapeutics will host a virtual presentation on June 30, 2025, featuring Phase 2 interim data for ARCT-810, an investigational mRNA therapeutic for ornithine transcarbamylase deficiency.
Phase 1/2 KEYMAKER-U02 Trial: Pembrolizumab Shows Manageable Safety Profile in Stage IIIB-D Melanoma
Neoadjuvant pembrolizumab, alone or combined with vibostolimab or gebasaxturev, demonstrated a manageable safety profile in stage IIIB-D melanoma patients, with 95% experiencing at least one adverse event.